yellow fever virus

yellow fever virus
Name	Yellow fever virus
Virus group	IV (+)ssRNA
Family	Flaviviridae
Genus	Flavivirus
Species	Yellow fever virus

yellow fever virus Yellow fever virus is an RNA virus of the family Flaviviridae that causes yellow fever, a hemorrhagic and hepatic disease of humans and some primates. First isolated in the early 20th century during efforts by international commissions, the virus has shaped public health policies in Panama Canal construction, influenced military campaigns like the Napoleonic Wars era colonial conflicts, and prompted development of the live-attenuated vaccine associated with the Rockefeller Foundation. Its ecology links urban centers in Lagos, Rio de Janeiro, and Kinshasa with sylvatic cycles in Amazon Rainforest, Congo Basin, and other tropical regions.

Virology

Yellow fever virus is an enveloped, positive-sense single-stranded RNA virus within the genus Flavivirus and family Flaviviridae, related to Dengue virus, Zika virus, and West Nile virus. The ~11 kb genome encodes a single polyprotein cleaved into structural proteins C, prM/M, and E and nonstructural proteins NS1–NS5, with NS5 containing the viral RNA-dependent RNA polymerase described in structural studies associated with institutions like the Pasteur Institute. Viral entry is mediated by the envelope (E) glycoprotein, which binds cell-surface receptors and undergoes low-pH triggered fusion in endosomes, a mechanism studied in laboratories at Johns Hopkins University and Rockefeller University. Genetic diversity clusters into multiple genotypes with geographic associations (West African, East/Central African, and South American lineages), inferred through phylogenetic analyses by groups at universities such as Imperial College London and University of São Paulo.

Transmission and Epidemiology

Transmission occurs via infected female Aedes and Haemagogus mosquitoes; principal urban vector Aedes aegypti drives peri-urban epidemics historically documented in port cities like New Orleans and Hamburg. Sylvatic (jungle) cycles involve nonhuman primates in ecologies such as the Amazon Rainforest and Congo Basin, with spillover to humans during occupational exposure like logging or mining in regions including Peru and Angola. Epidemic patterns have been altered by global trade and transport networks centered on hubs like Panama City and Lagos, and by vector expansion studied by agencies including the World Health Organization and Centers for Disease Control and Prevention. Notable historical outbreaks impacted places such as Philadelphia (1793) and Buenos Aires (1871), and modern control efforts focus on endemic countries in West Africa and Brazil.

Clinical Manifestations

Clinical disease ranges from a self-limited febrile illness to severe yellow fever characterized by jaundice, hemorrhage, and multi-organ dysfunction; severe cases have high case-fatality rates documented in outbreaks in Angola (2016) and Brazil (2017). The incubation period is typically 3–6 days, after which patients may progress from an acute febrile phase to a toxic phase with hepatic injury, renal failure, and coagulopathy—findings reported in clinical series from hospitals affiliated with University of São Paulo and Makerere University. Historical clinical descriptions from physicians involved with the Panama Canal project and military medical corps in campaigns such as the Spanish–American War informed modern case definitions.

Diagnosis

Diagnosis relies on a combination of clinical suspicion and laboratory testing. Direct detection methods include RT-PCR targeting the viral genome, performed in reference laboratories like those at the Pasteur Institute and CDC Atlanta. Serology demonstrates IgM and rising IgG titers detectable by enzyme-linked immunosorbent assay platforms validated by laboratories associated with Emory University and the London School of Hygiene & Tropical Medicine; cross-reactivity with related flaviviruses such as Dengue virus complicates interpretation, necessitating confirmatory neutralization tests conducted at national reference centers such as the Brazilian National Institute of Infectious Diseases.

Treatment and Management

No specific antiviral therapy with proven efficacy is licensed for yellow fever; management is supportive and includes intensive care measures for severe disease—fluid resuscitation, hemodynamic support, renal replacement therapy, and treatment of coagulopathy—protocols developed in tertiary centers like Mayo Clinic and Charité – Universitätsmedizin Berlin. Experimental antivirals and immunotherapies have been evaluated in preclinical studies at institutions such as National Institutes of Health and industry partners including Gilead Sciences, but none supersede vaccines or vector control for prevention. Clinical management also emphasizes infection control measures in hospitals and coordination with public health authorities such as the World Health Organization.

Prevention and Vaccination

Prevention rests on vaccination, vector control, and surveillance. The live-attenuated 17D vaccine, developed by researchers linked to the Rockefeller Foundation and initially produced in places such as Institut Pasteur, provides long-lasting immunity after a single dose and is included in immunization policies by agencies like the World Health Organization and national ministries of health in Ghana and Brazil. International health regulations and proof-of-vaccination requirements involve documents governed through standards influenced by the World Health Organization. Vector control strategies target urban Aedes aegypti populations, employing measures deployed in campaigns coordinated with organizations such as Pan American Health Organization and municipal authorities in cities like Rio de Janeiro.

Category:Flaviviruses Category:Arthropod-borne viral diseases